Dose-response evaluation of the interaction between sertraline and alprazolam in vivo

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 150-158

  Hassan, Paul C ^a,b   Sproule, Beth A ^a   Naranjo, Claudio A ^a,b   Herrmann, Nathan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; SERTRALINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC INHIBITION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MENTAL RECALL; MIXED FUNCTION OXYGENASES; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; SERTRALINE;

EID: 0034116448     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00006     Document Type: Article

References (55)

1. Lydiard R. Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Anxiety 1996;2: 61-70.
2. Kessler RC, McGonagle KA, Shao S, Nelson CB, Hughes M, Eshleman S, Wittchen H, Kendler K. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
3. Brown C, Schulberg H, Shear M. Phenomenology and severity of major depression and comorbid lifetime anxiety disorders in primary medical care practise. Anxiety 1996;2:210-8.
4. Gorman J, Coplan J. Comorbidity of depression and panic disorder. J Clin Psychiatry 1996;57:34-43.
5. Merikangas K, Angst J. Comorbidity and social phobia: evidence from clinical, epidemiologic, and genetic studies. Eur Arch Psychiatry Clin Neurosci 1995;244:297-303.
6. Mellinger G, Bolter M, Uhlenhuth E. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984;251:375-9.
7. Top 200 drugs. Am Druggist 1995;211:20-4.
8. Top 200 drugs. Am Druggist 1996;213:18-26.
9. IMS Canada. An exclusive IMS Canada ranking of the top 200 prescription drugs of 1995. Pharm Pract 1995;11:81-92.
10. IMS Canada. The top 200 drugs of 1996. Pharm Pract 1996; 12:67-79.
11. IMS Canada The top 200 drugs of 1997. Pharm Pract 1997; 13:29-40.
12. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-405.
13. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268-76.
14. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam is another substrate for human cytochrome P450-3A isoforms [letter]. J Clin Psychopharmacol 1998;18:256.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
16. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
17. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz J, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29:33-44.
18. Preskorn SH. Reducing, the risk of drug-drug interactions: a goal of rational drug development. J Clin Psychiatry 1996;57:3-6.
19. Lesser I, Lydiard J, Antal E, Rubin R, Ballenger J, DuPont R. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992;149:1556-62.
20. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:715-22.
21. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C. Doubleblind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-95.
22. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline and fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
23. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-6.
24. Levine B, Jenkins AJ, Smialek JE. Distribution of sertraline in post-mortem cases. J Anal Toxicol 1994;18:272-4.
25. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
26. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-9.
27. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991;104:323-7.
28. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-86.
29. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
30. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-9.
31. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
32. Shader RI, Dreyfuss D, Gerrein J, Harmatz JS, Allison S, Greenblatt DJ. Sedative effects and impaired learning and recall after single oral doses of lorazepam. Clin Pharmacol Ther 1986; 39:526-30.
33. Greenblatt DJ, Harmatz J, Dorsey C, Shader RI. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam and placebo. Clin Pharmacol Ther 1988;44:326-34.
34. Greenblatt DJ, Harmatz J, Gouthro T, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolitic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11.
35. Naranjo CA, Sellers EM, Kaplan H, Hamilton C, Khouw V. Acute kinetic and dynamic interactions of zimelidine with ethanol. Clin Pharmacol Ther 1984;36:654-60.
36. Sullivan J, Naranjo CA, Shaw C, Kaplan H, Kadlec K, Sellers EM. Kinetic and dynamic interactions of oral viqualine and ethanol in man Eur J Clin Pharmacol 1989;36:93-6.
37. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8.
38. Shaw C, Sullivan J, Kadlec K, Kaplan H, Naranjo C, Sellers E. Ethanol interactions with serotonin uptake selective and non-selective antidepressants: fluoxetine and amitriptyline. Hum Psychopharmacol 1989;4:113-20.
39. Ozdemir V, Naranjo C, Herrmann N, Reed K, Sellers E, Kalow W. Paroxetine potentiates the central nervous system side-effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-47.
40. Gibaldi M, Perrier D. Pharmacokinetics. New York: M. Dekker, 1975.
41. SPSS for Windows, release 6.0. Chicago: SPSS Inc., 1993.
42. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1994:245.
43. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry 1993;54[suppl 10]:4-11.
44. Greenblatt DJ, Javaid JI, Lockniskar A, Harmatz JS, Shader RI. Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. J Chromatogr 1990;534:202-7.
45. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly. Relation to antipyrine disposition. Arch Gen Psychiatry 1983;40:287-90.
46. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57[suppl 1]:20-3.
47. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Early stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 1994;47:355-60.
48. Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry 1988;49:58-61.
49. Preskorn SH, Alderman J, Greenblatt DJ, Horst WD. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997;33:659-65.
50. Zoloft (sertraline hydrochloride) product monograph. New York: Pfizer Inc., 1997.
51. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15:247-50.
52. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43:412-9.
53. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, Gips M, Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
54. Brøsen K, Hansen JG, Nielson KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
55. Ozdemir V, Naranjo C, Shulman RW, Hermann N, Sellers EM, Reed K, Kalow W. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998;18: 198-207.